Article
Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
Oncotarget - 16 May 2017
Hahn Andrew W, Gill David M, Maughan Benjamin, Agarwal Archana, Arjyal Lubina, Gupta Sumati, Streeter Jessica, Bailey Erin, Pal Sumanta K, Agarwal Neeraj
Abstract excerpt
INTRODUCTION: Tumor tissue and circulating tumor DNA (ctDNA) next-generation sequencing (NGS) testing are frequently performed to detect genomic alterations (GAs) to help guide treatment in metastatic renal cell carcinoma (mRCC), especially after progression on standard systemic therapy. Our objective was to assess if GAs detected by ctDNA NGS are different from those detected by tumor tissue NGS, specifically in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.